Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial

Jamie S. Street, W. Scott Clark, Kimberley S. Gannon, Jeffrey L. Cummings, Frank P. Bymaster, Roy N. Tamura, Steven J. Mitan, Deborah L. Kadam, Todd M. Sanger, Peter D. Feldman, Gary D. Tollefson, Alan Breier

Research output: Contribution to journalArticle

551 Citations (Scopus)

Abstract

Background: Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD. Methods: A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version. Results: Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P

Original languageEnglish (US)
Pages (from-to)968-976
Number of pages9
JournalArchives of General Psychiatry
Volume57
Issue number10
StatePublished - 2000

Fingerprint

olanzapine
Behavioral Symptoms
Nursing Care
Alzheimer Disease
Randomized Controlled Trials
Placebos
Nursing Homes
Aggression
Psychotic Disorders
Institutionalization
Delusions
Hallucinations
Therapeutics
Caregivers
Safety
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities : A double-blind, randomized, placebo-controlled trial. / Street, Jamie S.; Clark, W. Scott; Gannon, Kimberley S.; Cummings, Jeffrey L.; Bymaster, Frank P.; Tamura, Roy N.; Mitan, Steven J.; Kadam, Deborah L.; Sanger, Todd M.; Feldman, Peter D.; Tollefson, Gary D.; Breier, Alan.

In: Archives of General Psychiatry, Vol. 57, No. 10, 2000, p. 968-976.

Research output: Contribution to journalArticle

Street, JS, Clark, WS, Gannon, KS, Cummings, JL, Bymaster, FP, Tamura, RN, Mitan, SJ, Kadam, DL, Sanger, TM, Feldman, PD, Tollefson, GD & Breier, A 2000, 'Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial', Archives of General Psychiatry, vol. 57, no. 10, pp. 968-976.
Street, Jamie S. ; Clark, W. Scott ; Gannon, Kimberley S. ; Cummings, Jeffrey L. ; Bymaster, Frank P. ; Tamura, Roy N. ; Mitan, Steven J. ; Kadam, Deborah L. ; Sanger, Todd M. ; Feldman, Peter D. ; Tollefson, Gary D. ; Breier, Alan. / Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities : A double-blind, randomized, placebo-controlled trial. In: Archives of General Psychiatry. 2000 ; Vol. 57, No. 10. pp. 968-976.
@article{4bc9bc8db31944a7bc20c4fbdd21f73e,
title = "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial",
abstract = "Background: Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD. Methods: A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version. Results: Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P",
author = "Street, {Jamie S.} and Clark, {W. Scott} and Gannon, {Kimberley S.} and Cummings, {Jeffrey L.} and Bymaster, {Frank P.} and Tamura, {Roy N.} and Mitan, {Steven J.} and Kadam, {Deborah L.} and Sanger, {Todd M.} and Feldman, {Peter D.} and Tollefson, {Gary D.} and Alan Breier",
year = "2000",
language = "English (US)",
volume = "57",
pages = "968--976",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities

T2 - A double-blind, randomized, placebo-controlled trial

AU - Street, Jamie S.

AU - Clark, W. Scott

AU - Gannon, Kimberley S.

AU - Cummings, Jeffrey L.

AU - Bymaster, Frank P.

AU - Tamura, Roy N.

AU - Mitan, Steven J.

AU - Kadam, Deborah L.

AU - Sanger, Todd M.

AU - Feldman, Peter D.

AU - Tollefson, Gary D.

AU - Breier, Alan

PY - 2000

Y1 - 2000

N2 - Background: Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD. Methods: A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version. Results: Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P

AB - Background: Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD. Methods: A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version. Results: Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P

UR - http://www.scopus.com/inward/record.url?scp=0033799993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033799993&partnerID=8YFLogxK

M3 - Article

C2 - 11015815

AN - SCOPUS:0033799993

VL - 57

SP - 968

EP - 976

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 10

ER -